insulin aspart vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
insulin aspart · NovoLog
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07652528 (registry estimate)
No aligned efficacy figure on record for this race.
THDB0206
Developed by Adocia and partners
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin aspart | THDB0206 |
|---|---|---|
| HbA1c, change | -1.2% vs -1.3%vs IGlarNCT0097228319 other results
| —Not posted · NCT05834868 |
| Body weight, change (kg) | 2.7 vs 2.2vs Insulin GlargineNCT0488085011 other results
| —Not posted · NCT05834868 |
| HbA1c below 7% | 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978 | —Not posted · NCT05834868 |
| Fasting plasma glucose, change | -1.8 vs -1.6vs Insulin GlargineNCT048808505 other results
| —Not posted · NCT05834868 |
| 3-point MACE (% with event) | —Not posted · NCT01467323 | —Not posted · NCT05834868 |
HbA1c, change
- insulin aspart
- -1.2% vs -1.3%vs IGlarNCT00972283
19 other results
- -1.2% vs -1.2% NCT04880850
- -1.5% vs -1.4% NCT02762578
- -1.9% vs -1.7% NCT01513590
- -1.4% vs -1.4% NCT01059812
- -0.7% vs 0.1% NCT01388361
- -1.4% vs -1.2% NCT01272193
- -1.0% vs -1% NCT01045447
- -1.6% vs -1.7% NCT01045707
- -1.3% vs -1.3% NCT01009580
- -1.1% vs -1.1% NCT02648217
- -0.9% vs -1.1% NCT00972283
- -1.4% vs -1.3% NCT01045707
- -1.2% vs -1.3% NCT02453685
- -1.0% vs -1.1% NCT01165684
- -0.5% vs 0% NCT04538352
- 4.1% vs 3.4% NCT01966978
- -0.5% vs -0.5% NCT01194258
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- THDB0206
- —Not posted · NCT05834868
Body weight, change (kg)
- insulin aspart
- 2.7 vs 2.2vs Insulin GlargineNCT04880850
11 other results
- 2.8 vs 2.2 NCT02762578
- 2.8 vs 2 NCT01513590
- -1 vs 0.1 NCT01388361
- 0.7 vs 0.7 NCT01272193
- 1.1 vs 1.4 NCT01059812
- 0.9 vs 0.3 NCT01474538
- -8.6 vs 1.4 NCT04538352
- -0.6 vs 3.1 NCT01966978
- 1.5 vs 1.6 NCT01194258
- 0.3 vs 0.8 NCT00998335
- 0.1 vs -0.1 NCT00842361
- THDB0206
- —Not posted · NCT05834868
HbA1c below 7%
- insulin aspart
- 44% vs 20%vs Metformin, Insulin Detemir, Insulin AspartNCT01966978
- THDB0206
- —Not posted · NCT05834868
Fasting plasma glucose, change
- insulin aspart
- -1.8 vs -1.6vs Insulin GlargineNCT04880850
5 other results
- -3.0 vs -1.6 NCT02762578
- -4.4 vs -3.0 NCT01513590
- -0.1 vs -1.2 NCT01388361
- -2 vs -4.4 NCT02648217
- 6.4 vs 4.9 NCT00998335
- THDB0206
- —Not posted · NCT05834868
3-point MACE (% with event)
- insulin aspart
- —Not posted · NCT01467323
- THDB0206
- —Not posted · NCT05834868
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDB0206: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. insulin aspart: 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin aspart |
|---|---|
| Dropout rate | 0%once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT02453685 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.5% NCT04880850 · Phase 3 · registry result, not featured evidence 2.2% NCT02906917 · Phase 3 · registry result, not featured evidence 4.2%BID NCT02762578 · Phase 3 · registry result, not featured evidence 7.6%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 15.4%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 12.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 5.1% NCT01513590 · Phase 3 · registry result, not featured evidence 13.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 6.6%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 6.4%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 6.8%OD NCT01272193 · Phase 3 · registry result, not featured evidence 13.1%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 15.5%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 17.7% NCT01045707 · Phase 3 · registry result, not featured evidence 12.1% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results— NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02453685 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT04880850 · Phase 3 · registry result, not featured evidence 0.4% NCT02906917 · Phase 3 · registry result, not featured evidence 0.3%BID NCT02762578 · Phase 3 · registry result, not featured evidence 0%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 2.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 1.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence — NCT01474538 · Phase 3 · registry result, not featured evidence 1% NCT01513590 · Phase 3 · registry result, not featured evidence 5.7% NCT01388361 · Phase 3 · registry result, not featured evidence · combination —IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence —IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 0.7%OD NCT01272193 · Phase 3 · registry result, not featured evidence 3.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 4.1%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 0%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 1.9% NCT01045707 · Phase 3 · registry result, not featured evidence 1.8% NCT01009580 · Phase 3 · registry result, not featured evidence — NCT01194258 · Phase 2 · registry result, not featured evidence — NCT00842361 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 22.5%once weeklya NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 24 more results11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 8.4% NCT02453685 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 7.6% NCT04880850 · Phase 3 · registry result, not featured evidence 6.8% NCT02906917 · Phase 3 · registry result, not featured evidence 4.4%BID NCT02762578 · Phase 3 · registry result, not featured evidence 3.8%twice daily NCT02648217 · Phase 3 · registry result, not featured evidence 5.2%IDegAsp Simple NCT01680341 · Phase 3 · registry result, not featured evidence 7.5%IDegAsp Step Wise NCT01680341 · Phase 3 · registry result, not featured evidence 11.8% NCT01474538 · Phase 3 · registry result, not featured evidence 6.6% NCT01513590 · Phase 3 · registry result, not featured evidence 4.6% NCT01388361 · Phase 3 · registry result, not featured evidence · combination 0.7%IDegAsp Simple NCT01365507 · Phase 3 · registry result, not featured evidence 4.3%IDegAsp Step Wise NCT01365507 · Phase 3 · registry result, not featured evidence 3.4%OD NCT01272193 · Phase 3 · registry result, not featured evidence 8.2%BID NCT01059812 · Phase 3 · registry result, not featured evidence 18.5%once daily NCT00972283 · Phase 3 · registry result, not featured evidence 4.3%once daily NCT01045447 · Phase 3 · registry result, not featured evidence 11.3% NCT01045707 · Phase 3 · registry result, not featured evidence 8.5% NCT01009580 · Phase 3 · registry result, not featured evidence 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence 3% NCT00842361 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | once weeklya pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination show 22 more resultsgi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 12.7% headache 7.2% arthralgia 6.6% NCT02453685 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence covid-19 8.6% diarrhoea 5.2% diabetic retinopathy 4.1% NCT04880850 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.2% back pain 6% NCT02906917 · Phase 3 · registry result, not featured evidence BID upper respiratory tract infection 21.1% diabetic retinopathy 10% viral upper respiratory tract infection 2.5% NCT02762578 · Phase 3 · registry result, not featured evidence twice daily blood glucose decreased 35.4% upper respiratory tract infection 6.2% pyrexia 3.1% NCT02648217 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.4% nasopharyngitis 8.9% headache 6.7% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.9% influenza 9% upper respiratory tract infection 7.5% NCT01680341 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% rhinitis allergic 4.2% back pain 3.4% NCT01474538 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.7% NCT01513590 · Phase 3 · registry result, not featured evidence nausea 20.7% diarrhoea 10.3% nasopharyngitis 10.3% NCT01388361 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 9% nasopharyngitis 6% NCT01365507 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 10.7% nasopharyngitis 7.9% NCT01365507 · Phase 3 · registry result, not featured evidence OD nasopharyngitis 22.4% diabetic retinopathy 5.4% NCT01272193 · Phase 3 · registry result, not featured evidence BID nasopharyngitis 18.3% upper respiratory tract infection 7.5% diabetic retinopathy 6.8% NCT01059812 · Phase 3 · registry result, not featured evidence once daily nasopharyngitis 16.5% upper respiratory tract infection 16.3% headache 9.4% NCT00972283 · Phase 3 · registry result, not featured evidence once daily headache 8.7% nasopharyngitis 7.4% diarrhoea 5.2% NCT01045447 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% hypertension 7.5% back pain 6% NCT01045707 · Phase 3 · registry result, not featured evidence nasopharyngitis 11.6% upper respiratory tract infection 7.6% headache 5.8% NCT01009580 · Phase 3 · registry result, not featured evidence uterine leiomyoma 6.7% arthralgia 6.5% headache 6.5% NCT01194258 · Phase 2 · registry result, not featured evidence nasopharyngitis 9.1% supraventricular extrasystoles 6.1% NCT00842361 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin aspart
show 19 more results
show 12 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
+ 45 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin aspart's landscape · THDB0206's landscape